United States Cancer Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Cancer Type (Colorectal Cancer, Prostate Cancer, Breast Cancer, and Lung Cancer), By Biomarker Type (Metabolomic Biomarkers, Genetic Biomarkers, Epigenetic Biomarkers, and Proteomic Biomarkers), and US Cancer Biomarkers Market Insights, Industry Trend, Forecasts to 2035

USA Cancer Biomarkers Market Insights Forecasts to 2035

• The United States Cancer Biomarkers Market Size is Expected to Grow at a CAGR of around 10.98% from 2025 to 2035
• The USA Cancer Biomarkers Market Size is expected to hold a significant share by 2035

According to a research report published by Spherical Insights & Consulting, the US Cancer Biomarkers Market Size is Anticipated to hold a Significant Share by 2035, Growing at a CAGR of 10.98% from 2025 to 2035. The market growth is ascribed to the rising incidence of cancer, a rising proportion of research studies, and the growing unhealthy lifestyles.

Market Overview

The development, manufacturing, and use of biological molecules that signal the presence or progression of cancer are the main focus of the US cancer biomarkers market. These molecules help with early detection, diagnosis, prognosis, and treatment monitoring, which in turn allows for personalized therapies. In cancer, abnormal cells proliferate uncontrollably, leading to genetic abnormalities. These alterations may be acquired later in life or inherited from a parent. There are two primary types of cancer: solid tumor cancers, which arise in organs or tissues such as the breast, prostate, lung, and colorectal cancers, and blood (hematologic) cancers, which begin in blood cells or tissues such as leukemia, lymphoma, and multiple myeloma. Biomarkers are biological indicators of a biological state that are used to track and forecast a population's or an individual's health. They can be applied separately or in combination to evaluate a person's health or illness. Cancer has been detected, screened for, diagnosed, treated, and tracked using biomarkers. Anti-cancer medications have historically destroyed both cancerous and healthy cells. More focused treatments, on the other hand, have been created to only destroy cancer cells while leaving healthy cells intact. Finding a typical biomarker for cancer aids in the development of treatments that target the biomarker, lowering treatment expenses and toxicity risks. Since genetic abnormalities frequently underlie the development of cancer, genetic studies are useful in the study of cancer. Certain cancers may be easier to identify and treat with the use of particular DNA or RNA markers.

Various government initiatives drive the market growth. For instance, the government of the United States launched and reestablished the Cancer Moonshot. In 2022, the Cancer Moonshot aimed to achieve a decade's worth of progress in cancer prevention, diagnosis, and treatment in five years, funded by the 21st Century Cures Act, by involving patients, advocates, researchers, and clinicians to utilize resources from government, academia, and the private sector.

The increasing prevalence of cancer escalates the need for cancer biomarkers for the diagnosis of cancer, leading to market growth. For instance, the data provided by the National Cancer Institute states that cancer has a substantial impact on society; in the US, an estimated 2,041,910 new cases and 618,120 deaths are anticipated in 2025. The following cancers are common: non-Hodgkin lymphoma, uterine corpus, pancreatic, thyroid, leukemia, liver, prostate, lung, colon, rectum, skin, bladder, kidney, renal pelvis, and liver and intrahepatic bile duct cancer. Breast, prostate, lung, colon, rectum, skin, bladder, kidney, renal pelvis, non-Hodgkin lymphoma, and pancreatic cancer are the most prevalent forms of cancer, which have a substantial social burden.

Report Coverage

This research report categorizes the market for the US cancer biomarkers market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US cancer biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US cancer biomarkers market.

Driving Factors

The rising incidence of cancer, growing research on cancer biomarkers, growing use of biomarkers in drug development and discovery, and technological advancements are all contributing factors to the growth of the cancer biomarkers market. One of the main factors influencing the demand for cancer biomarkers is the move toward personalized medicine in the treatment of cancer. With uses in diagnosis, prognosis, and targeted therapy selection, biomarkers are becoming more and more significant in personalized medicine. It is anticipated that partnerships between major industry participants and research institutions will propel market expansion. Companion diagnostics, personalized medicine, disease risk assessment, and drug development and discovery all make use of cancer biomarkers. Pharmaceutical firms are spending money on the study and creation of new biomarkers for the detection and management of cancer.

Restraining Factors

The complexity of the disease, high costs, regulatory obstacles, uneven reimbursement practices, and data privacy issues may impede the market growth.

Market Segmentation

The USA cancer biomarkers market share is classified into cancer type and biomarker type.

• The breast cancer segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US cancer biomarkers market is segmented by cancer type into colorectal cancer, prostate cancer, breast cancer, and lung cancer. Among these, the breast cancer segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the genetic mutation, obesity, hormonal influence, and cellular changes with growing age.

• The genetic biomarkers segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US cancer biomarkers market is segmented by biomarker type into metabolomic biomarkers, genetic biomarkers, epigenetic biomarkers, and proteomic biomarkers. Among these, the genetic biomarkers segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the early identification of the disease, targeted therapy enhances the diagnosis, and analyzes the gene expression in cancer cells.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US cancer biomarkers market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Genomic Health, Inc.
• PerkinElmer Inc.
• Qiagen N.V.
• Merck & Co., Inc.
• Roche Diagnostics
• Myriad Genetics
• Agilent Technologies
• Pfizer Inc.
• Abbott Laboratories
• Others

Recent Developments:

• In April 2025, The Precision Dosimetry Imaging Biomarker (PDIB) project, launched by the Foundation for the National Institutes of Health (FNIH), aims to develop more effective radiopharmaceutical therapies (RPTs) or radioligand therapies (RLTs) to improve survival rates and quality of life for cancer patients. PDIB transforms how therapeutic radiation is measured, allowing for direct delivery to tumors, sparing healthy cells, and reducing side effects.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the US cancer biomarkers market based on the below-mentioned segments:

US Cancer Biomarkers Market, By Cancer Type

• Colorectal Cancer
• Prostate Cancer
• Breast Cancer
• Lung Cancer

US Cancer Biomarkers Market, By Biomarker Type

• Metabolomic Biomarkers
• Genetic Biomarkers
• Epigenetic Biomarkers
• Proteomic Biomarkers